Acumen Pharmaceuticals (ABOS) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Tenaya Therapeutics (TNYA) over the past year, gaining 11.7% versus a loss of 70.3%. Over five years, ABOS leads with a -84.5% price change compared with -97.4% for TNYA. Acumen Pharmaceuticals is the larger company by market cap ($151.9 million vs $122.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | TNYA |
|---|---|---|
| Share price | $2.10 | $0.5442 |
| Market cap | $151.87M | $122.03M |
| 1-day change | 0.00% | +2.02% |
| YTD return | -0.47% | -23.57% |
| 1-year return | +11.70% | -70.26% |
| 5-year return | -84.50% | -97.35% |
| EPS (TTM) | $-1.64 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $2.35 |
| 52-week low | $1.50 | $0.5211 |
| Distance from 52-week high | -41.67% | -76.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +261.90% | +488.02% |
| Average volume | 439.10K | 2.26M |
| Shares outstanding | 72.32M | 224.23M |
| Employees | 60 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed TNYA by 82.0 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
ABOS vs TNYA FAQ
Which is bigger, Acumen Pharmaceuticals or Tenaya Therapeutics?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $151.87M compared with $122.03M for Tenaya Therapeutics (TNYA).
Which stock has performed better over the past year, ABOS or TNYA?
ABOS returned +11.70% over the past 12 months, compared with -70.26% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.